Background: Extramammary Paget's disease of the vulva (EPDV) is a rare adenocarcinoma in situ of the vulvar skin and is often resected with involved margins due to its reticular growth pattern. Adjuvant treatment with the immunomodulator imiquimod may be suitable to avoid repeated and mutilating surgery. Case Presentation: We present the case of a 73-year-old woman with EPDV, initially treated with surgical resection and re-resection for involved margins. Final histology revealed Paget's disease of the left vulva with 8 cm in the largest diameter and again involved margins. Subsequently, topical therapy with imiquimod 5% cream twice weekly was applied for 3 months. Vulvoscopy and local biopsies confirmed complete remission (CR). Based on a literature search using PubMed and the Cochrane Central Register of Controlled Trials, 21 reports on the therapeutic efficacy of imiquimod in 70 women with EPDV have been published. Pooled rates of CR and partial remission were 71% (50/70) and 16% (11/70), respectively. There were 4 cases of disease progression under imiquimod and the therapy was generally well tolerated with mild to moderate local reactions in >50% of cases. Conclusion: EPDV is a rare genital neoplasia and may be successfully treated with the topical immunomodulator imiquimod. Specifically, adjuvant imiquimod is a feasible and efficacious treatment option for women with involved resection margins after surgery.

Journal Section:
Editor's choice
Keywords:
Paget’s disease, Superficial skin cancer, Vulva, Extramammary Paget’s disease, Genital neoplasia
1.
Barmon D, Kataki AC, Imchen L, Sharma JD: Extra mammary Paget's disease of the vulva. J Midlife Health 2012;3:100-102.
2.
Curtin JP, Rubin SC, Jones WB, Hoskins WJ, Lewis JL Jr: Paget's disease of the vulva. Gynecol Oncol 1990;39:374-377.
3.
Gonçalves Amorim A, Batista Fraga Mendes B, Neves Ferreira R, Chambô Filho A: Paget disease of the vulva: diagnosis by immunohistochemistry. Case Rep Dermatol Med 2015;2015:162483.
4.
Edey KA, Allan E, Murdoch JB, Cooper S, Bryant A: Interventions for the treatment of Paget's disease of the vulva. Cochrane Database Syst Rev 2013;10:CD009245.
5.
Shaco-Levy R, Bean SM, Vollmer RT, Jewell E, Jones EL, Valdes CL, Bentley RC, Selim MA, Robboy SJ: Paget disease of the vulva: a study of 56 cases. Eur J Obstet Gynecol Reprod Biol 2010;149:86-91.
6.
Black D, Tornos C, Soslow RA, Awtrey CS, Barakat RR, Chi DS: The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva. Gynecol Oncol 2007;104:547-550.
7.
Jeon MS, Jung GY, Lee JH, Kang KW, No KW: Extramammary Paget disease of the vulva: minimal excision with adjuvant radiation treatment for optimal aesthetic results. Tumori 2015, Epub ahead of print.
8.
Roh HJ, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Paget's disease of the vulva: evaluation of recurrence relative to symptom duration, volumetric excision of lesion, and surgical margin status. Acta Obstet Gynecol Scand 2010;89:962-965.
9.
Crawford D, Nimmo M, Clement PB, Thomson T, Benedet JL, Miller D, Gilks CB: Prognostic factors in Paget's disease of the vulva: a study of 21 cases. Int J Gynecol Pathol 1999;18:351-359.
10.
Dahl MV: Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002;47(4 suppl):S205-S208.
11.
Kobold S, Wiedemann G, Rothenfußer S, Endres S: Modes of action of TLR7 agonists in cancer therapy. Immunotherapy 2014;6:1085-1095.
12.
Jiang J, Dong L, Shi HT, Guo XY, Qin B, Wang Y, Li H: Imiquimod inhibits the growth of SGC-7901 cells in vitro through induction of autophagy and apoptosis. Mol Med Rep 2015;13:393-397.
13.
de Witte CJ, van de Sande AJ, van Beekhuizen HJ, Koeneman MM, Kruse AJ, Gerestein CG: Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review. Gynecol Oncol 2015;139:377-384.
14.
Grimm C, Polterauer S, Natter C, Rahhal J, Hefler L, Tempfer CB, Heinze G, Stary G, Reinthaller A, Speiser P: Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol 2012;120:152-159.
15.
Luyten A, Sörgel P, Clad A, Gieseking F, Maass-Poppenhusen K, Lellé RJ, Harter P, Buttmann N, Petry KU: Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German colposcopy network. J Am Acad Dermatol 2014;70:644-650.
16.
Sanderson P, Innamaa A, Palmer J, Tidy J: Imiquimod therapy for extramammary Paget's disease of the vulva: a viable non-surgical alternative. J Obstet Gynaecol 2013;33:479-483.
17.
Baiocchi G, Begnami MD, Fukazawa EM, Surima WS, Badiglian-Filho L, Costa FD, Oliveira RA, Faloppa CC, Kumagai LY, Soares FA: Conservative management of extramammary Paget disease with imiquimod. J Low Genit Tract Dis 2012;16:59-63.
18.
Tonguc E, Güngor T, Var T, Ozat M, Sahin I, Sirvan L: Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature. Arch Gynecol Obstet 2011;283:97-101.
19.
Bertozzi S, Londero AP, Fruscalzo A, Marchesoni D, Lellé RJ: Paget disease of the vulva: resolution after local treatment with imiquimod - report of a case and review of the literature. Gynakol Geburtshilfliche Rundsch 2009;49:326-330.
20.
Marchitelli C, Peremateu MS, Sluga MC, Berasategui MT, Lopez DG, Wernicke A, Velazco A, Gogorza S: Treatment of primary vulvar paget disease with 5% imiquimod cream. J Low Genit Tract Dis 2014;18:347-350.
21.
Hatch KD, Davis JR: Complete resolution of Paget disease of the vulva with imiquimod cream. J Low Genit Tract Dis 2008;12:90-94.
22.
Sendagorta E, Herranz P, Feito M, Ramírez P, Floristán U, Feltes R, Benito DM, Casado M: Successful treatment of three cases of primary extramammary Paget's disease of the vulva with imiquimod - proposal of a therapeutic schedule. J Eur Acad Dermatol Venereol 2010;24:490-492.
23.
Frances L, Pascual JC, Leiva-Salinas M, Betlloch I: Extramammary Paget disease successfully treated with topical imiquimod 5% and tazarotene. Dermatol Ther 2014;27:19-20.
24.
Anton C, Luiz AV, Carvalho FM, Baracat EC, Carvalho JP: Clinical treatment of vulvar Paget's disease: a case report. Clinics (Sao Paulo) 2011;66:1109-1111.
25.
Geisler JP, Manahan KJ: Imiquimod in vulvar Paget's disease: a case report. J Reprod Med 2008;53:811-812.
26.
Matin RN, Gibbon K, Rizvi H, Harwood CA, Cerio R: Cutaneous mucinous carcinoma arising in extramammary Paget disease of the perineum. Am J Dermatopathol 2011;33:705-709.
27.
Toledo F, Silvestre JF, Cuesta L, Ballester I, Latorre N, Monteagudo A: Sequential use with imiquimod and surgery in extramammary Paget's disease. Dermatol Ther 2012;25:​82-85.
28.
Hiraldo-Gamero A, Gómez-Moyano E, Segura-Palacios JM, Sánchez-Fajardo F, Sanz-Trelles A: Extramammary Paget disease treated with 5% imiquimod cream. Actas Dermosifiliogr 2011;102:554-556.
29.
Wang LC, Blanchard A, Judge DE, Lorincz AA, Medenica MM, Busbey S: Successful treatment of recurrent extramammary Paget's disease of the vulva with topical imiquimod 5% cream. J Am Acad Dermatol 2003;49:769-772.
30.
Wagner G, Heine M, Sachse MM: Extramammary Paget disease: successful therapy with imiquimod 5% cream. Hautarzt 2012;63:42-46.
31.
Choi JH, Jue MS, Kim EJ, Joh OJ, Song KY, Park HJ: Extramammary paget disease: minimal surgical therapy. Ann Dermatol 2013;25:213-217.
32.
Cooper JC, Hew KE, Audlin KM, Im DD, Matsuo K: Synchronous of breast and vulvar Paget's disease: a case report. Eur J Gynaecol Oncol 2012;33:534-536.
33.
Feldmeyer L, Kerl K, Kamarashev J, de Viragh P, French LE: Treatment of vulvar Paget disease with topical imiquimod: a case report and review of the literature. J Dermatol Case Rep 2011;5:42-46.
34.
Misery L: Treatment of genital Paget's skin disease with topical imiquimod: severe adverse events. J Dermatolog Treat 2007;18:191-192.
35.
Gilson RJ, Shupack JL, Friedman-Kien AE, Conant MA, Weber JN, Nayagam AT, Swann RV, Pietig DC, Smith MH, Owens ML: A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod study group. AIDS 1999;13:2397-2404.
36.
Anadkat MJ, Bogucki BA: Development of adenopathy during the use of topical imiquimod. J Am Acad Dermatol 2011;64:e75-e77.
37.
Taylor CL, Maslen M, Kapembwa M: A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect 2006;82:227-228.
38.
Li W, Xin H, Ge L, Song H, Cao W: Induction of vitiligo after imiquimod treatment of condylomata acuminata. BMC Infect Dis 2014;14:329.
39.
Rosenblatt A, de Campos Guidi HG: Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases. Int J STD AIDS 2012;23:909-910.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.